ES2691493T3 - Métodos para tratar la neutropenia usando agonistas retinoides - Google Patents

Métodos para tratar la neutropenia usando agonistas retinoides Download PDF

Info

Publication number
ES2691493T3
ES2691493T3 ES13800873.5T ES13800873T ES2691493T3 ES 2691493 T3 ES2691493 T3 ES 2691493T3 ES 13800873 T ES13800873 T ES 13800873T ES 2691493 T3 ES2691493 T3 ES 2691493T3
Authority
ES
Spain
Prior art keywords
cells
bacteria
retinoic acid
neutrophils
csf
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES13800873.5T
Other languages
English (en)
Spanish (es)
Inventor
Lingtao Wu
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Childrens Hospital Los Angeles
Original Assignee
Childrens Hospital Los Angeles
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Childrens Hospital Los Angeles filed Critical Childrens Hospital Los Angeles
Application granted granted Critical
Publication of ES2691493T3 publication Critical patent/ES2691493T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/196—Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/382—Heterocyclic compounds having sulfur as a ring hetero atom having six-membered rings, e.g. thioxanthenes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
ES13800873.5T 2012-06-07 2013-06-07 Métodos para tratar la neutropenia usando agonistas retinoides Active ES2691493T3 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261656815P 2012-06-07 2012-06-07
US201261656815P 2012-06-07
PCT/US2013/044828 WO2013185105A1 (en) 2012-06-07 2013-06-07 Methods for treating neutropenia using retinoid agonists

Publications (1)

Publication Number Publication Date
ES2691493T3 true ES2691493T3 (es) 2018-11-27

Family

ID=49712715

Family Applications (1)

Application Number Title Priority Date Filing Date
ES13800873.5T Active ES2691493T3 (es) 2012-06-07 2013-06-07 Métodos para tratar la neutropenia usando agonistas retinoides

Country Status (13)

Country Link
US (1) US11116738B2 (https=)
EP (1) EP2858636B1 (https=)
JP (1) JP6295249B2 (https=)
KR (1) KR102083046B1 (https=)
CN (1) CN104519879B (https=)
AU (1) AU2013270674B2 (https=)
BR (1) BR112014030279A2 (https=)
CA (1) CA2874850A1 (https=)
ES (1) ES2691493T3 (https=)
MX (1) MX365321B (https=)
NZ (1) NZ702415A (https=)
RU (1) RU2650962C2 (https=)
WO (1) WO2013185105A1 (https=)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102083046B1 (ko) 2012-06-07 2020-02-28 칠드런＇스 하스피틀 로스 앤젤레스 레티노이드 작용제를 이용하여 호중구감소증을 치료하기 위한 방법
EP2969031A4 (en) 2013-03-15 2017-03-08 Avisenna Cosmetics LLC Topical compositions for reducing aging effects
MX2016010699A (es) * 2014-02-18 2017-10-11 Children's Hospital Los Angeles Composiciones y metodos para tratar neutropenia.
PL3277272T3 (pl) 2015-03-31 2022-01-24 Syros Pharmaceuticals, Inc. Sposoby stratyfikacji pacjentów do leczenia agonistami receptora kwasu retinowego
US9868994B2 (en) 2016-04-08 2018-01-16 Syros Pharmaceuticals, Inc. Methods of stratifying patients for treatment with retinoic acid receptor-α agonists
WO2018067946A1 (en) * 2016-10-06 2018-04-12 Syros Pharmaceuticals, Inc. Methods of treating patients with a retinoic acid receptor-alpha agonist and an anti-cd38 antibody
EP3743722A4 (en) * 2018-01-26 2022-03-02 Agency for Science, Technology and Research NEUTROPHIL SUBTYPES
CN113969261B (zh) * 2020-07-06 2024-04-09 苏州市立医院(北区) 三步法快速测定中性粒细胞趋化的方法
US20220378727A1 (en) * 2021-05-14 2022-12-01 The University Of Hong Kong Dry powder formulations of tamibarotene for pulmonary and intranasal delivery
FI131561B1 (en) * 2023-12-28 2025-06-30 Faron Pharmaceuticals Oy CLEVER-1 INHIBITOR TO PROMOTE HEMATOLOGICAL RECOVERY WHEN USING CHEMOTHERAPY

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5691196A (en) * 1992-12-31 1997-11-25 American Cyanamid Company Recombinant nucleic acid containing a response element
US5965606A (en) 1995-12-29 1999-10-12 Allergan Sales, Inc. Methods of treatment with compounds having RAR.sub.α receptor specific or selective activity
EP0957918A1 (en) * 1996-12-19 1999-11-24 American Cyanamid Company Method of treating or inhibiting neutropenia
MXPA03002045A (es) 2000-09-08 2003-07-24 Amgen Inc Composiciones analogas de factor estimulador de colonias de granulocitos y metodos para su elaboracion.
US7119061B2 (en) 2002-11-18 2006-10-10 Vicuron Pharmaceuticals, Inc. Dalbavancin compositions for treatment of bacterial infections
KR20060018851A (ko) 2003-05-16 2006-03-02 교와 핫꼬 고교 가부시끼가이샤 조직 파괴를 수반하는 질환의 예방 및/또는 치료제
EP1621191A1 (en) * 2004-07-29 2006-02-01 Werner Bollag Treatment of inflammatory diseases by RXR Antagonists
JP2008509928A (ja) * 2004-08-13 2008-04-03 アノーメド インコーポレイテッド 前駆／幹細胞を動員するためのケモカインの組み合わせ
ATE476981T1 (de) 2004-12-02 2010-08-15 Venus Remedies Ltd Zusammensetzungen zur bekämpfung von beta- lactamase-vermittelter antibiotischer resistenz mittels beta-lactamase-hemmern für injektionen
US20090111786A1 (en) * 2004-12-03 2009-04-30 Glass Christopher K Compounds that Prevent Macrophage Apoptosis and Uses Thereof
TR201819157T4 (tr) * 2006-05-16 2019-01-21 Io Therapeutics Llc Kemoterapi Ve Veya Radyasyon Terapisinin Yan Etkilerinin Tedavisinde Kullanıma Yönelik Rar Antagonisti Veya Ters Agonisti
EP2143428B1 (en) * 2007-03-30 2015-11-04 TMRC Co., Ltd. Tamibarotene capsule preparation
WO2009070844A1 (en) * 2007-12-06 2009-06-11 Csl Limited Method of inhibition of leukemic stem cells
US8580516B2 (en) 2008-09-05 2013-11-12 University Of Chicago Methods and compositions for direct detection of DNA damage
CN102612371B (zh) 2009-10-19 2014-03-19 莱拉营养食品有限公司 含有多聚乙酰的提取物，分馏物和混合物及它们的应用
RU2446173C1 (ru) 2010-08-13 2012-03-27 Зао "Биокад" Новый функционально активный, высокоочищенный стабильный конъюгат гранулоцитарного колониестимулирующего фактора (г-ксф) с полиэтиленгликолем с пролонгированным биологическим действием, пригодный для медицинского применения, и иммунобиологическое средство на его основе
CN102380090A (zh) 2010-08-31 2012-03-21 健能隆医药技术（上海）有限公司 G-csf二聚体在治疗嗜中性粒细胞减少症中的应用
CA2826386C (en) 2011-02-08 2020-04-28 FUJIFILM Cellular Dynamics, Inc. Hematopoietic precursor cell production by programming
JP6242868B2 (ja) * 2012-05-08 2017-12-06 リセラ・コーポレイションＬｙｃｅｒａ Ｃｏｒｐｏｒａｔｉｏｎ ＲＯＲγのアゴニストとしての使用のためおよび疾患の処置のためのテトラヒドロ［１，８］ナフチリジンスルホンアミドおよび関連化合物
KR102083046B1 (ko) 2012-06-07 2020-02-28 칠드런＇스 하스피틀 로스 앤젤레스 레티노이드 작용제를 이용하여 호중구감소증을 치료하기 위한 방법
DE102012011766B3 (de) 2012-06-15 2013-12-19 Voith Patent Gmbh Getriebeeinheit
CN110946993A (zh) 2014-01-03 2020-04-03 上海泽生科技开发股份有限公司 纽兰格林制剂的配方
MX2016010699A (es) 2014-02-18 2017-10-11 Children's Hospital Los Angeles Composiciones y metodos para tratar neutropenia.

Also Published As

Publication number Publication date
JP2015523346A (ja) 2015-08-13
AU2013270674A1 (en) 2014-12-18
JP6295249B2 (ja) 2018-03-14
AU2013270674B2 (en) 2017-12-07
KR102083046B1 (ko) 2020-02-28
WO2013185105A1 (en) 2013-12-12
HK1208630A1 (en) 2016-03-11
US11116738B2 (en) 2021-09-14
MX365321B (es) 2019-05-29
EP2858636A1 (en) 2015-04-15
US20150164836A1 (en) 2015-06-18
EP2858636A4 (en) 2016-06-01
CN104519879B (zh) 2018-10-02
BR112014030279A2 (pt) 2017-09-12
KR20150035983A (ko) 2015-04-07
CA2874850A1 (en) 2013-12-12
RU2014153988A (ru) 2016-07-27
MX2014014930A (es) 2015-07-06
CN104519879A (zh) 2015-04-15
NZ702415A (en) 2016-04-29
EP2858636B1 (en) 2018-09-05
RU2650962C2 (ru) 2018-04-18

Similar Documents

Publication Publication Date Title
ES2691493T3 (es) Métodos para tratar la neutropenia usando agonistas retinoides
Frenette et al. Platelets roll on stimulated endothelium in vivo: an interaction mediated by endothelial P-selectin.
Davenpeck et al. Activation of human leukocytes reduces surface P-selectin glycoprotein ligand-1 (PSGL-1, CD162) and adhesion to P-selectin in vitro
Schoefinius et al. Mesenchymal stromal cell-derived extracellular vesicles provide long-term survival after total body irradiation without additional hematopoietic stem cell support
US20200171089A1 (en) Use of Post-Transplant Cyclophosphamide Treated Allogenic Marrow Infiltrating Lymphocytes to Augment Anti-Tumor Immunity
EP2925329B1 (en) Use of post-transplant cyclophosphamide treated allogeneic marrow infiltrating lymphocytes to augment anti-tumor immunity
Zeis et al. Allogeneic MHC‐mismatched activated natural killer cells administered after bone marrow transplantation provide a strong graft‐versus‐leukaemia effect in mice
Wallach-Dayan et al. Cutting edge: FasL+ immune cells promote resolution of fibrosis
Goldman et al. The triterpenoid RTA 408 is a robust mitigator of hematopoietic acute radiation syndrome in mice
EP3068875B1 (en) Post-natal hematopoietic endothelial cells and their isolation and use
Filip et al. The peripheral chimerism of bone marrow–derived stem cells after transplantation: regeneration of gastrointestinal tissues in lethally irradiated mice
Stiff et al. Anti-CD33 monoclonal antibody and etoposide/cytosine arabinoside combinations for the ex vivo purification of bone marrow in acute nonlymphocytic leukemia
CN117980470A (zh) 治疗性nk细胞群
US20210177905A1 (en) Therapeutic substances, their preparation and diagnostic procedure
Kellner et al. Ex vivo generation of umbilical cord blood T regulatory cells expressing the homing markers CD62L and cutaneous lymphocyte antigen
HK1208630B (en) Methods for treating neutropenia using retinoid agonists
Pinola et al. Adhesion molecules involved in the interaction of LGL/NK cells and human endothelial cells stimulated with Salmonella bacteria
Lahat et al. Concomitant Effect of 2′‐Deoxycoformycin on Natural Killer Cell Activity and Tumour Cell Sensitivity to Lysis in Hairy Cell Leukaemia—Discordant Effects of Alpha Interferon
Rivas Interaction of Histophilus Somni with Bovine Neutrophils and Macrophages: Effect on Pro-coagulant Activity
HATAYAMA et al. Regulation of Bcl-2 Expression in Glioma Cells by All-trans Retinoic Acid
Beligaswatte et al. rHuG-CSF in Peripheral Blood Progenitor Cell Transplantation
AU2014348603A1 (en) Post-natal hematopoeitic endothelial cells and their isolation and use